133 related articles for article (PubMed ID: 27561716)
1. Development of single and mixed isoform selectivity PI3Kδ inhibitors by targeting Asn836 of PI3Kδ.
Miller MS; Mountford SJ; Pinson JA; Zheng Z; Künzli M; Patel V; Hogg SJ; Shortt J; Jennings IG; Thompson PE
Bioorg Med Chem Lett; 2016 Oct; 26(19):4790-4794. PubMed ID: 27561716
[TBL] [Abstract][Full Text] [Related]
2. Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
Zhu J; Pan P; Li Y; Wang M; Li D; Cao B; Mao X; Hou T
Mol Biosyst; 2014 Mar; 10(3):454-66. PubMed ID: 24336903
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies.
Liu X; Wang A; Liang X; Liu J; Zou F; Chen C; Zhao Z; Deng Y; Wu H; Qi Z; Wang B; Wang L; Liu F; Xu Y; Wang W; Fernandes SM; Stone RM; Galinsky IA; Brown JR; Loh T; Griffin JD; Zhang S; Weisberg EL; Zhang X; Liu J; Liu Q
Oncotarget; 2016 Aug; 7(33):53515-53525. PubMed ID: 27447747
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of PI3Kβ-selective inhibition revealed by reciprocal mutagenesis.
Zheng Z; Miller MS; Jennings IG; Thompson PE
ACS Chem Biol; 2013 Apr; 8(4):679-83. PubMed ID: 23360067
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ.
Collier PN; Messersmith D; Le Tiran A; Bandarage UK; Boucher C; Come J; Cottrell KM; Damagnez V; Doran JD; Griffith JP; Khare-Pandit S; Krueger EB; Ledeboer MW; Ledford B; Liao Y; Mahajan S; Moody CS; Roday S; Wang T; Xu J; Aronov AM
J Med Chem; 2015 Jul; 58(14):5684-8. PubMed ID: 26121481
[TBL] [Abstract][Full Text] [Related]
6. Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma.
Ameriks MK; Venable JD
Curr Top Med Chem; 2009; 9(8):738-53. PubMed ID: 19689378
[TBL] [Abstract][Full Text] [Related]
7. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents.
Ward SG; Finan P
Curr Opin Pharmacol; 2003 Aug; 3(4):426-34. PubMed ID: 12901953
[TBL] [Abstract][Full Text] [Related]
8. Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances.
Liu X; Wang A; Liang X; Chen C; Liu J; Zhao Z; Wu H; Deng Y; Wang L; Wang B; Wu J; Liu F; Fernandes SM; Adamia S; Stone RM; Galinsky IA; Brown JR; Griffin JD; Zhang S; Loh T; Zhang X; Wang W; Weisberg EL; Liu J; Liu Q
Oncotarget; 2016 May; 7(22):32641-51. PubMed ID: 27081697
[TBL] [Abstract][Full Text] [Related]
9. Selective PI3Kδ inhibitors, a review of the patent literature.
Norman P
Expert Opin Ther Pat; 2011 Nov; 21(11):1773-90. PubMed ID: 22017414
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration.
Perry MWD; Björhall K; Bonn B; Carlsson J; Chen Y; Eriksson A; Fredlund L; Hao H; Holden NS; Karabelas K; Lindmark H; Liu F; Pemberton N; Petersen J; Rodrigo Blomqvist S; Smith RW; Svensson T; Terstiege I; Tyrchan C; Yang W; Zhao S; Öster L
J Med Chem; 2017 Jun; 60(12):5057-5071. PubMed ID: 28520415
[TBL] [Abstract][Full Text] [Related]
11. Isoform selective phosphoinositide 3-kinase gamma and delta inhibitors and their therapeutic potential.
Ghigo A; Hirsch E
Recent Pat Inflamm Allergy Drug Discov; 2008 Jan; 2(1):1-10. PubMed ID: 19075988
[TBL] [Abstract][Full Text] [Related]
12. The effect of phosphatidylinositol-3 kinase inhibition on matrix metalloproteinase-9 and reactive oxygen species release from chronic obstructive pulmonary disease neutrophils.
Gupta V; Khan A; Higham A; Lemon J; Sriskantharajah S; Amour A; Hessel EM; Southworth T; Singh D
Int Immunopharmacol; 2016 Jun; 35():155-162. PubMed ID: 27049289
[TBL] [Abstract][Full Text] [Related]
13. Structural Determinants of Isoform Selectivity in PI3K Inhibitors.
Miller MS; Thompson PE; Gabelli SB
Biomolecules; 2019 Feb; 9(3):. PubMed ID: 30813656
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.
Safina BS; Baker S; Baumgardner M; Blaney PM; Chan BK; Chen YH; Cartwright MW; Castanedo G; Chabot C; Cheguillaume AJ; Goldsmith P; Goldstein DM; Goyal B; Hancox T; Handa RK; Iyer PS; Kaur J; Kondru R; Kenny JR; Krintel SL; Li J; Lesnick J; Lucas MC; Lewis C; Mukadam S; Murray J; Nadin AJ; Nonomiya J; Padilla F; Palmer WS; Pang J; Pegg N; Price S; Reif K; Salphati L; Savy PA; Seward EM; Shuttleworth S; Sohal S; Sweeney ZK; Tay S; Tivitmahaisoon P; Waszkowycz B; Wei B; Yue Q; Zhang C; Sutherlin DP
J Med Chem; 2012 Jun; 55(12):5887-900. PubMed ID: 22626259
[TBL] [Abstract][Full Text] [Related]
15. Potent and highly selective benzimidazole inhibitors of PI3-kinase delta.
Murray JM; Sweeney ZK; Chan BK; Balazs M; Bradley E; Castanedo G; Chabot C; Chantry D; Flagella M; Goldstein DM; Kondru R; Lesnick J; Li J; Lucas MC; Nonomiya J; Pang J; Price S; Salphati L; Safina B; Savy PP; Seward EM; Ultsch M; Sutherlin DP
J Med Chem; 2012 Sep; 55(17):7686-95. PubMed ID: 22877085
[TBL] [Abstract][Full Text] [Related]
16. Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kδ inhibitors.
Terstiege I; Perry M; Petersen J; Tyrchan C; Svensson T; Lindmark H; Öster L
Bioorg Med Chem Lett; 2017 Feb; 27(3):679-687. PubMed ID: 28017532
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of cytokine production by PI3Kdelta in human monocytes upon acute and chronic inflammatory conditions.
Molnarfi N; Brandt KJ; Gruaz L; Dayer JM; Burger D
Mol Immunol; 2008 Jul; 45(12):3419-27. PubMed ID: 18471882
[TBL] [Abstract][Full Text] [Related]
18. Discovery and biological evaluation of novel pyrazolopyridine derivatives as potent and orally available PI3Kδ inhibitors.
Hamajima T; Takahashi F; Kato K; Mukoyoshi K; Yoshihara K; Yamaki S; Sugano Y; Moritomo A; Yamagami K; Yokoo K; Fukahori H
Bioorg Med Chem; 2018 May; 26(9):2410-2419. PubMed ID: 29631787
[TBL] [Abstract][Full Text] [Related]
19. Structure, function and inhibition of the phosphoinositide 3-kinase p110α enzyme.
Flanagan JU; Shepherd PR
Biochem Soc Trans; 2014 Feb; 42(1):120-4. PubMed ID: 24450638
[TBL] [Abstract][Full Text] [Related]
20. Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3K
Allen RA; Brookings DC; Powell MJ; Delgado J; Shuttleworth LK; Merriman M; Fahy IJ; Tewari R; Silva JP; Healy LJ; Davies GCG; Twomey B; Cutler RM; Kotian A; Crosby A; McCluskey G; Watt GF; Payne A
J Pharmacol Exp Ther; 2017 Jun; 361(3):429-440. PubMed ID: 28442583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
